
    
      The study is a multi-central, controlled, randomized Phase III trial. The protocol has been
      approved by the Ethics Committee of Beijing Cancer Hospital. The primary endpoint is the
      3-year progression-free survival (PFS) rate. The secondary endpoints are the overall survival
      (OS) and safety.
    
  